Abstract
We review the current status of the role and function of the mitochondrial DNA (mtDNA) in the etiology of autism spectrum disorders (ASD) and the interaction of nuclear and mitochondrial genes. High lactate levels reported in about one in five children with ASD may indicate involvement of the mitochondria in energy metabolism and brain development. Mitochondrial disturbances include depletion, decreased quantity or mutations of mtDNA producing defects in biochemical reactions within the mitochondria. A subset of individuals with ASD manifests copy number variation or small DNA deletions/duplications, but fewer than 20 percent are diagnosed with a single gene condition such as fragile X syndrome. The remaining individuals with ASD have chromosomal abnormalities (e.g., 15q11-q13 duplications), other genetic or multigenic causes or epigenetic defects. Next generation DNA sequencing techniques will enable better characterization of genetic and molecular anomalies in ASD, including defects in the mitochondrial genome particularly in younger children.
Keywords: Autism spectrum disorders (ASD), mitochondrial DNA (mtDNA) mutations and depletion, oxidative stress, nuclear genes, lactate/pyruvate ratios, genetic causation, copy number variation, Heteroplasmy, nucleotide polymorphisms, fragile X syndromes
Current Genomics
Title: Genetics and Mitochondrial Abnormalities in Autism Spectrum Disorders:A Review
Volume: 12 Issue: 5
Author(s): Sukhbir Dhillon, Jessica A. Hellings and Merlin G. Butler
Affiliation:
Keywords: Autism spectrum disorders (ASD), mitochondrial DNA (mtDNA) mutations and depletion, oxidative stress, nuclear genes, lactate/pyruvate ratios, genetic causation, copy number variation, Heteroplasmy, nucleotide polymorphisms, fragile X syndromes
Abstract: We review the current status of the role and function of the mitochondrial DNA (mtDNA) in the etiology of autism spectrum disorders (ASD) and the interaction of nuclear and mitochondrial genes. High lactate levels reported in about one in five children with ASD may indicate involvement of the mitochondria in energy metabolism and brain development. Mitochondrial disturbances include depletion, decreased quantity or mutations of mtDNA producing defects in biochemical reactions within the mitochondria. A subset of individuals with ASD manifests copy number variation or small DNA deletions/duplications, but fewer than 20 percent are diagnosed with a single gene condition such as fragile X syndrome. The remaining individuals with ASD have chromosomal abnormalities (e.g., 15q11-q13 duplications), other genetic or multigenic causes or epigenetic defects. Next generation DNA sequencing techniques will enable better characterization of genetic and molecular anomalies in ASD, including defects in the mitochondrial genome particularly in younger children.
Export Options
About this article
Cite this article as:
Dhillon Sukhbir, A. Hellings Jessica and G. Butler Merlin, Genetics and Mitochondrial Abnormalities in Autism Spectrum Disorders:A Review, Current Genomics 2011; 12(5) . https://dx.doi.org/10.2174/138920211796429745
DOI https://dx.doi.org/10.2174/138920211796429745 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic:VIP and PACAP: Novel Approaches to Brain Functions and Neuroprotection (Executive Guest Editors: Seiji Shioda and Illana Gozes)]
Current Pharmaceutical Design The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design Nitric Oxide and Teratogenesis: An Update
Current Pharmaceutical Design Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets 5-ht6 Receptors
Current Drug Targets - CNS & Neurological Disorders Vasculogenic and Angiogenic Pathways in Moyamoya Disease
Current Medicinal Chemistry Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions
Current Neuropharmacology Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Genetic Variations in CHRNA7 or CHRFAM7 and Susceptibility to Dementia
Current Drug Targets Regulation of miRNA Processing and miRNA Mediated Gene Repression in Cancer
MicroRNA Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Therapeutic Hypothermia as a Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Brain Injury and Traumatic Brain Injury
Current Molecular Medicine